Haematopoietic Stem Cell Transplantation and Allogeneic Transplantation
Research activity is centred on allogeneic haematopoietic cell transplantation in adults receiving grafts from an HLA-matched sibling donor, with attention to immune-mediated complications that arise after transplant.
- HLA-matched sibling donor transplantation
- Post-transplant immune reconstitution
- Graft-versus-host disease
Clinical interest extends to transplant settings where donor compatibility is fully established and immune tolerance remains a central therapeutic concern.
Graft-versus-Host Disease Prevention and Treatment
The sponsor focuses on the prevention and management of graft-versus-host disease in the transplant setting, with particular emphasis on immune control after allogeneic haematopoietic stem cell transplantation.
- Acute graft-versus-host disease
- Immune-mediated transplant complications
- Post-transplant prophylaxis
Interest is directed toward therapies that support immune regulation while preserving transplant compatibility and clinical stability.
Regulatory T Cell Therapies
Investigations include regulatory T cell–based immunotherapy, especially inducible HLA-G positive regulatory T cells, as a strategy to modulate immune responses after transplantation.
- iG-Tregs
- Adoptive cell therapy
- Immune tolerance induction
The therapeutic focus includes cellular approaches designed to support donor-recipient immune balance in the transplant environment.
Transplant Immunology and Cellular Immunotherapy
Research interest lies in transplant immunology and cellular immunotherapy, with emphasis on donor-derived immune cell products for controlling post-transplant inflammatory responses.
- Donor-derived immune cell products
- Immune tolerance
- Cell-based immunomodulation
The clinical landscape reflects a strong focus on immune intervention in haematology and transplant-related care.
